Kepler Universitaetsklinikum GmbH

The Clinic for Neurology 2 at Kepler Universitaetsklinikum is actively investigating treatments for acute myeloid leukemia. It also studies myeloid leukemia in children with Down syndrome.

• Evaluating a novel drug combination to enhance event‑free survival in de‑novo AML
• Testing the addition of an antibody‑drug conjugate in relapsed pediatric AML
• Comparing treosulfan‑based and BuCyMel conditioning regimens to lower graft‑versus‑host disease
• Collecting biological samples for toxicity and translational studies

The goal is to improve survival rates, reduce transplant‑related complications, and generate valuable biomarker data for future therapeutic strategies.

Researchers are focusing on persistent neuropathic conditions such as chronic pain due to diabetic polyneuropathy. They also address post‑operative peripheral neuropathy. Another target is central neuropathy of any origin. Finally, the team evaluates chronic back pain.

• Assessing the add‑on agent AP707 for diabetic polyneuropathy‑related pain
• Evaluating AP707 in individuals with trauma‑induced peripheral neuropathy
• Testing AP707 efficacy in central neuropathic pain irrespective of cause
• Investigating AP707 as a supplemental treatment for chronic low‑back pain

These studies aim to provide more effective pain relief and improve daily functioning for patients suffering from long‑term neuropathic discomfort.

The Linz facility hosts seven clinical trials coordinated by 36 investigators, spanning hematology and pain management.

• Running studies that target both blood cancers and neuropathic pain
• Collaborating with international sites to broaden patient enrollment
• Utilizing the neurology department’s expertise to assess neurological outcomes
• Gathering biospecimens for future translational research initiatives

This multidisciplinary effort reflects the hospital’s dedication to advancing patient‑focused therapies across blood disorders and chronic pain syndromes.